{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:51:32Z","timestamp":1775483492960,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Tokyo Women\u2019s Medical University Career Development Center for Medical Professionals"},{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>W2TPD, a twice-weekly teriparatide administration regimen, was used on 163 patients. The continuation rate was 47%, with only one new fracture. Even after performing antiresorptive therapy, spine BMD increased significantly in the majority of groups. W2TPD demonstrated good efficacy and tolerability in a real-world sequential osteoporosis treatment model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Teriparatide is the most commonly administered daily, but there are also once-weekly and twice-weekly regimens. The former demonstrated high efficacy in increasing bone mineral density (BMD) and preventing new fractures; however, the continuation rate was reported to be low due to a high incidence of side effects. As a result, the twice-weekly teriparatide administration schedule (W2TPD) was created. In this study, we conducted a real-world clinical evaluation of its efficacy as part of a sequential osteoporosis treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 163 patients with osteoporosis who were treated with W2TPD. Patients treated with W2TPD were divided into five groups based on their prior medication use: treatment-na\u00efve (N), post-denosumab (post-D), post-bisphosphonate (post-B), post-romosozumab (post-R), and post-SERM (post-S). We examined treatment continuation rates, adverse events, and changes in BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall treatment continuation rate was 47.9%, with only one patient developing a new fracture during treatment. Gastrointestinal side effects, such as heartburn, nausea, and vomiting, were common. The percent changes in spine BMD were 10%, 5.2%, 5%,\u2009\u2212\u20091.5%, and 12.3% in the N, post-D, post-B, post-R, and post-S groups, respectively. Meanwhile, hips were found in 3.1%, 0.4%, 1.5%, 0%, and 2.2%, respectively. In terms of spine BMD, all groups except post-R had responder rates greater than 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The continuation rate of W2TPD was 47% and resulted in particularly favorable BMD gains in the spine. It was also discovered to be effective in increasing BMD even when following bisphosphonate treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-025-01622-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:15:24Z","timestamp":1763547324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of twice-weekly teriparatide acetate administration in osteoporosis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-9287","authenticated-orcid":false,"given":"Ayako","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Maruki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Terayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideharu","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1759720x17732562","volume":"9","author":"WF Lems","year":"2017","unstructured":"Lems WF, Raterman HG (2017) Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Ther Adv Musculoskelet Dis 9:299\u2013316. https:\/\/doi.org\/10.1177\/1759720x17732562","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00774-009-0080-8","volume":"27","author":"N Yoshimura","year":"2009","unstructured":"Yoshimura N, Muraki S, Oka H et al (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis\/osteoporosis against disability study. J Bone Miner Metab 27:620\u2013628. https:\/\/doi.org\/10.1007\/s00774-009-0080-8","journal-title":"J Bone Miner Metab"},{"key":"1622_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/jbmr.4821","volume":"38","author":"CW Sing","year":"2023","unstructured":"Sing CW, Lin TC, Bartholomew S et al (2023) Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality. J Bone Miner Res 38:1064\u20131075. https:\/\/doi.org\/10.1002\/jbmr.4821","journal-title":"J Bone Miner Res"},{"key":"1622_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11657-023-01230-0","volume":"18","author":"EJ Yeh","year":"2023","unstructured":"Yeh EJ, Gitlin M, Sorio F, McCloskey E (2023) Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among postmenopausal women across eight European countries. Arch Osteoporos 18:68. https:\/\/doi.org\/10.1007\/s11657-023-01230-0","journal-title":"Arch Osteoporos"},{"key":"1622_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, J\u00f6nsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342. https:\/\/doi.org\/10.1007\/s00198-003-1490-4","journal-title":"Osteoporos Int"},{"key":"1622_CR6","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","volume":"22","author":"S Morin","year":"2011","unstructured":"Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22:2439\u20132448. https:\/\/doi.org\/10.1007\/s00198-010-1480-2","journal-title":"Osteoporos Int"},{"key":"1622_CR7","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1\u201334] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106. https:\/\/doi.org\/10.1210\/jc.2011-3479","journal-title":"J Clin Endocrinol Metab"},{"key":"1622_CR8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","volume":"30","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T, Shiraki M, Fukunaga M et al (2019) Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321\u20132331. https:\/\/doi.org\/10.1007\/s00198-019-05111-6","journal-title":"Osteoporos Int"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11657-018-0466-0","volume":"13","author":"T Usui","year":"2018","unstructured":"Usui T, Funagoshi M, Seto K, Ide K, Tanaka S, Kawakami K (2018) Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. Arch Osteoporos 13:54. https:\/\/doi.org\/10.1007\/s11657-018-0466-0","journal-title":"Arch Osteoporos"},{"key":"1622_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00774-022-01347-1","volume":"40","author":"R Fujita","year":"2022","unstructured":"Fujita R, Endo T, Takahata M et al (2022) Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis. J Bone Miner Metab 40:782\u2013789. https:\/\/doi.org\/10.1007\/s00774-022-01347-1","journal-title":"J Bone Miner Metab"},{"key":"1622_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpdd.687","volume":"9","author":"Y Kumagai","year":"2020","unstructured":"Kumagai Y, Ose A, Tanaka K, Sugimoto T (2020) Safety profiles, pharmacokinetics, and changes in bone turnover markers after twice-weekly subcutaneous administration of teriparatide in healthy Japanese postmenopausal women: a single-blind randomized study. Clin Pharmacol Drug Dev 9:87\u201396. https:\/\/doi.org\/10.1002\/cpdd.687","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Miner Res"},{"key":"1622_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.11138\/ccmbm\/2013.10.1.015","volume":"10","author":"G Guglielmi","year":"2013","unstructured":"Guglielmi G, di Chio F, DelleVergini MR, La Porta M, Nasuto M, Di Primio LA (2013) Early diagnosis of vertebral fractures. Clin Cases Miner Bone Metab 10:15\u20138. https:\/\/doi.org\/10.11138\/ccmbm\/2013.10.1.015","journal-title":"Clin Cases Miner Bone Metab"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2014.04.007","volume":"47","author":"E Cavalier","year":"2014","unstructured":"Cavalier E, Souberbielle JC, Gadisseur R, Dubois B, Krzesinski JM, Delanaye P (2014) Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 47:1227\u20131230. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.04.007","journal-title":"Clin Biochem"},{"key":"1622_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/030079905x75096","volume":"22","author":"R Eastell","year":"2006","unstructured":"Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61\u201366. https:\/\/doi.org\/10.1185\/030079905x75096","journal-title":"Curr Med Res Opin"},{"key":"1622_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1570-0232(02)00431-2","volume":"781","author":"Y Igarashi","year":"2002","unstructured":"Igarashi Y, Lee MY, Matsuzaki S (2002) Acid phosphatases as markers of bone metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 781:345\u2013358. https:\/\/doi.org\/10.1016\/s1570-0232(02)00431-2","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1622_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s002239900497","volume":"63","author":"BJ Gertz","year":"1998","unstructured":"Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102\u2013106. https:\/\/doi.org\/10.1007\/s002239900497","journal-title":"Calcif Tissue Int"},{"key":"1622_CR18","first-page":"2015","volume":"41","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Blake GM (2000) Different approaches to bone densitometry. J Nucl Med 41:2015\u20132025","journal-title":"J Nucl Med"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.bone.2006.06.007","volume":"39","author":"JC Gallagher","year":"2006","unstructured":"Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268\u20131275","journal-title":"Bone"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","volume":"120","author":"PD Miller","year":"2019","unstructured":"Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC et al (2019) Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone 120:137\u2013140. https:\/\/doi.org\/10.1016\/j.bone.2018.10.015","journal-title":"Bone"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00198-016-3581-z","volume":"27","author":"R Niimi","year":"2016","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2016) A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int 27:2845\u20132853. https:\/\/doi.org\/10.1007\/s00198-016-3581-z","journal-title":"Osteoporos Int"},{"key":"1622_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226. https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J Bone Miner Res"},{"key":"1622_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32:1999\u20132009. https:\/\/doi.org\/10.1007\/s00198-021-05925-3","journal-title":"Osteoporos Int"},{"key":"1622_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00774-024-01570-y","volume":"43","author":"A Tominaga","year":"2024","unstructured":"Tominaga A, Wada K, Kato Y, Okazaki K (2024) Responders and non-responders to romosozumab treatment. J Bone Miner Metab 43:18\u201321. https:\/\/doi.org\/10.1007\/s00774-024-01570-y","journal-title":"J Bone Miner Metab"},{"key":"1622_CR25","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"1622_CR26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"1622_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"1622_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"1622_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/nejmoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215. https:\/\/doi.org\/10.1056\/nejmoa031975","journal-title":"N Engl J Med"},{"key":"1622_CR30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/nejm200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/nejm200105103441904","journal-title":"N Engl J Med"},{"key":"1622_CR31","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932\u20131941. https:\/\/doi.org\/10.1359\/jbmr.2003.18.11.1932","journal-title":"J Bone Miner Res"},{"key":"1622_CR32","doi-asserted-by":"publisher","first-page":"117189","DOI":"10.1016\/j.bone.2024.117189","volume":"187","author":"R Takahashi","year":"2024","unstructured":"Takahashi R, Chiba K, Okazaki N et al (2024) Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: sub-analysis by quantitative computed tomography from the TERABIT study. Bone 187:117189. https:\/\/doi.org\/10.1016\/j.bone.2024.117189","journal-title":"Bone"},{"key":"1622_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","volume":"99","author":"R Zebaze","year":"2017","unstructured":"Zebaze R, Takao-Kawabata R, Peng Y, Zadeh AG, Hirano K, Yamane H et al (2017) Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99:80\u201384. https:\/\/doi.org\/10.1016\/j.bone.2017.03.042","journal-title":"Bone"},{"key":"1622_CR34","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/boneres.2017.2","volume":"5","author":"A Takakura","year":"2017","unstructured":"Takakura A, Lee JW, Hirano K, Isogai Y, Ishizuya T, Takao-Kawabata R et al (2017) Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats. Bone Res 5:17002. https:\/\/doi.org\/10.1038\/boneres.2017.2","journal-title":"Bone Res"},{"key":"1622_CR35","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s00198-010-1454-4","volume":"22","author":"M Saito","year":"2011","unstructured":"Saito M, Marumo K, Kida Y, Ushiku C, Kato S, Takao-Kawabata R et al (2011) Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1\u201334) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 22:2373\u20132383. https:\/\/doi.org\/10.1007\/s00198-010-1454-4","journal-title":"Osteoporos Int"},{"key":"1622_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00774-019-01051-7","volume":"38","author":"H Tsuchie","year":"2020","unstructured":"Tsuchie H, Miyakoshi N, Kasukawa Y, Abe H, Masutani N, Shimada Y (2020) Factors affecting continuation of weekly teriparatide administration in rural areas. J Bone Miner Metab 38:248\u2013253. https:\/\/doi.org\/10.1007\/s00774-019-01051-7","journal-title":"J Bone Miner Metab"},{"key":"1622_CR37","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703. https:\/\/doi.org\/10.1210\/er.2004-0006","journal-title":"Endocr Rev"},{"key":"1622_CR38","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s11255-025-04383-8","volume":"57","author":"D Vetrano","year":"2025","unstructured":"Vetrano D, Aguanno F, Passaseo A, Barbuto S, Tondolo F, Catalano V et al (2025) Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience. Int Urol Nephrol 57:1965\u20131975. https:\/\/doi.org\/10.1007\/s11255-025-04383-8","journal-title":"Int Urol Nephrol"},{"key":"1622_CR39","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J et al (2016) Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27:1441\u20131450. https:\/\/doi.org\/10.1007\/s00198-015-3377-6","journal-title":"Osteoporos Int"},{"key":"1622_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1744-9987.12867","volume":"24","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Nakazawa D, Nishio S et al (2020) Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study. Ther Apher Dial 24:146\u2013153. https:\/\/doi.org\/10.1111\/1744-9987.12867","journal-title":"Ther Apher Dial"},{"key":"1622_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/1744-9987.12867","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1111\/1744-9987.12867","journal-title":"Lancet"},{"key":"1622_CR42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860. https:\/\/doi.org\/10.1210\/jc.2007-0711","journal-title":"J Clin Endocrinol Metab"},{"key":"1622_CR43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kodama Y et al (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int 33:1265\u20131273. https:\/\/doi.org\/10.1007\/s00198-021-06261-2","journal-title":"Osteoporos Int"},{"key":"1622_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1620\/tjem.254.57","volume":"254","author":"Y Mori","year":"2021","unstructured":"Mori Y, Izumiyama T, Mori N, Aizawa T (2021) The effect of teriparatide for the treatment of multiple spontaneous clinical vertebral fractures after discontinuation of denosumab in a female patient with rheumatoid arthritis: a case report. Tohoku J Exp Med 254:57\u201361. https:\/\/doi.org\/10.1620\/tjem.254.57","journal-title":"Tohoku J Exp Med"},{"key":"1622_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M (2019) Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 285:381\u2013394. https:\/\/doi.org\/10.1111\/joim.12873","journal-title":"J Intern Med"},{"key":"1622_CR46","doi-asserted-by":"publisher","first-page":"ziae131","DOI":"10.1093\/jbmrpl\/ziae131","volume":"8","author":"T Kobayakawa","year":"2024","unstructured":"Kobayakawa T, Kanayama Y, Hirano Y, Yukishima T, Nakamura Y (2024) Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab. JBMR Plus 8:ziae131. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae131","journal-title":"JBMR Plus"},{"key":"1622_CR47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","volume":"34","author":"M Kashii","year":"2023","unstructured":"Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34:563\u2013572. https:\/\/doi.org\/10.1007\/s00198-022-06642-1","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01622-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:17:13Z","timestamp":1766524633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01622-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01622-4","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The performed procedures complied with the 1964 Helsinki Declaration and its subsequent amendments and were approved by the Tokyo Women\u2019s Medical University Ethics Committee (No. 2022-0063).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was obtained from all participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Ayako Tominaga, Maruki Hideyuki, Yoshiharu Kato, Yasushi Terayama, Hideharu Nishi, and Ken Okazaki declare that they have no conflict of interest. Keiji Wada received a speaking fee from Amgen, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"144"}}